These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30943928)

  • 1. CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.
    Rothé F; Maetens M; Rouas G; Paesmans M; Van den Eynde M; Van Laethem JL; Vergauwe P; Deboever G; Bareche Y; Vandeputte C; Ignatiadis M; Hendlisz A
    BMC Cancer; 2019 Apr; 19(1):304. PubMed ID: 30943928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
    Hendlisz A; Golfinopoulos V; Deleporte A; Paesmans M; Mansy HE; Garcia C; Peeters M; Annemans L; Vandeputte C; Maetens M; Borbath I; Dresse D; Houbiers G; Fried M; Awada A; Piccart M; Laethem JL; Flamen P
    BMC Cancer; 2013 Apr; 13():190. PubMed ID: 23587148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
    Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
    Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
    PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.
    Lu CY; Tsai HL; Uen YH; Hu HM; Chen CW; Cheng TL; Lin SR; Wang JY
    Br J Cancer; 2013 Mar; 108(4):791-7. PubMed ID: 23422758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).
    Karoui M; Rullier A; Piessen G; Legoux JL; Barbier E; De Chaisemartin C; Lecaille C; Bouche O; Ammarguellat H; Brunetti F; Prudhomme M; Regimbeau JM; Glehen O; Lievre A; Portier G; Hartwig J; Goujon G; Romain B; Lepage C; Taieb J;
    Ann Surg; 2020 Apr; 271(4):637-645. PubMed ID: 31356278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
    Grothey A; Sargent DJ
    J Clin Oncol; 2005 May; 23(15):3311-3. PubMed ID: 15908645
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
    Pernot S; Badoual C; Terme M; Castan F; Cazes A; Bouche O; Bennouna J; Francois E; Ghiringhelli F; De La Fouchardiere C; Samalin E; Bachet JB; Borg C; Ducreux M; Marcheteau E; Stanbury T; Gourgou S; Malka D; Taieb J
    Eur J Cancer; 2017 Jul; 79():15-22. PubMed ID: 28456090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
    Emile JF; Julié C; Le Malicot K; Lepage C; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Dimet S; Boulagnon-Rombi C; Allard MA; Penault-Llorca F; Bennouna J; Laurent-Puig P; Taieb J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Eur J Cancer; 2017 Sep; 82():16-24. PubMed ID: 28651158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.